Home
Browse
Search
Statistics
About
Usage
PMID: 25267914
Csanady L, Torocsik B
Structure-activity analysis of a CFTR channel potentiator: Distinct molecular parts underlie dual gating effects.
J Gen Physiol. 2014 Oct;144(4):321-36. doi: 10.1085/jgp.201411246.,
[PubMed]
Sentences
No.
Mutations
Sentence
Comment
32
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:32:212
status:
NEW
view ABCC7 p.Lys1250Ala details
Second, it increased by approximately threefold both the rate of opening of WT channels (step C1O1) and the slow rate of nonhydrolytic closure (step O1C1) of catalytically inactive mutants, such as
K1250A
CFTR in which lack of the conserved NBD2 Walker A lysine side chain abrogates ATP hydrolysis at site 2 (Ramjeesingh et al., 1999).
Login to comment
46
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 25267914:46:186
status:
NEW
view ABCC7 p.Gly551Asp details
The first CFTR potentiator to enter clinical use, VX-770 (Ivacaftor; Vertex Pharmaceuticals [Van Goor et al., 2009]), was recently approved for the treatment of CF patients carrying the
G551D
(Ramsey et al., 2011) and other rare CFTR mutations.
Login to comment
49
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:49:52
status:
NEW
view ABCC7 p.Lys1250Ala details
ABCC7 p.Glu1371Ser
X
ABCC7 p.Glu1371Ser 25267914:49:27
status:
NEW
view ABCC7 p.Glu1371Ser details
pore-block measurements on
E1371S
(see Fig. 2 A) or
K1250A
CFTR (see Figs. 3 and 4), surviving currents of channels opened in resting oocytes as the result of endogenous phosphorylation were also used (Csan&#e1;dy and T&#f6;r&#f6;csik, 2014).
Login to comment
70
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:70:63
status:
NEW
view ABCC7 p.Lys1250Ala details
M A T E R I A L S A N D M E T H O D S Molecular biology WT and
K1250A
CFTR cDNA subcloned into the pGEMHE plasmid (Vergani et al., 2003) was linearized using NheI and transcribed in vitro using T7 polymerase (mMESSAGE kit; Ambion).
Login to comment
77
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:77:186
status:
NEW
view ABCC7 p.Lys1250Ala details
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:77:220
status:
NEW
view ABCC7 p.Lys1250Ala details
MgATP (Sigma-Aldrich) was made up at 400 mM (adjusted to pH 7.1 with NMDG) and diluted into the bath solution at 2 and 10 mM final concentrations, respectively, for recordings on WT and
K1250A
CFTR (the higher [ATP] for
K1250A
was used to compensate for its reduced ATP-binding affinity [Vergani et al., 2003]).
Login to comment
83
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:83:207
status:
NEW
view ABCC7 p.Lys1250Ala details
ABCC7 p.Glu1371Ser
X
ABCC7 p.Glu1371Ser 25267914:83:174
status:
NEW
view ABCC7 p.Glu1371Ser details
A convenient macroscopic assay for measuring fractional effects on average ion flux rates through bursting channels is provided by nonhydrolytic mutant CFTR channels such as
E1371S
(Vergani et al., 2003) or
K1250A
.
Login to comment
86
ABCC7 p.Glu1371Ser
X
ABCC7 p.Glu1371Ser 25267914:86:186
status:
NEW
view ABCC7 p.Glu1371Ser details
As expected, application of MOPS&#e032; at a concentration of 80 mM, approximately ninefold its own KI (Fig. 2 A, green bars), reversibly reduced macroscopic current through locked-open
E1371S
channels by almost 90% (Fig. 2 A).
Login to comment
87
ABCC7 p.Glu1371Ser
X
ABCC7 p.Glu1371Ser 25267914:87:110
status:
NEW
view ABCC7 p.Glu1371Ser details
In the presence of 80 mM MOPS&#e032; , addition of NPPB (Fig. 2 A, brown bars) further suppressed locked-open
E1371S
currents in a dose-dependent manner; however, further fractional reduction by 210 &#b5;M NPPB (&#e07a;10-fold its own KI) was only &#e07a;50% (Fig. 2 A, yellow box magnified in inset).
Login to comment
106
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:106:78
status:
NEW
view ABCC7 p.Lys1250Ala details
We next probed acceleration by NPPB of the slow nonhydrolytic closing rate of
K1250A
CFTR channels (Fig. 2 F, gray bar) upon removal of ATP (Fig. 2 E, gray fit lines and time constants).
Login to comment
110
ABCC7 p.Glu1371Ser
X
ABCC7 p.Glu1371Ser 25267914:110:28
status:
NEW
view ABCC7 p.Glu1371Ser details
(A) Macroscopic locked-open
E1371S
CFTR current at &#e032;120 mV after removal of ATP from the bath; exposures to various NPPB concentrations (brown bars) in the continued presence of 80 mM MOPS&#e032; (green bar; magnified in yellow inset).
Login to comment
117
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:117:16
status:
NEW
view ABCC7 p.Lys1250Ala details
(E) Macroscopic
K1250A
CFTR currents at &#e032;40 mV elicited by brief exposures to 10 mM ATP in the absence or presence of blockers. Current relaxations after ATP removal were fitted by single exponentials with time constants indicated.
Login to comment
118
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:118:16
status:
NEW
view ABCC7 p.Lys1250Ala details
(F) Macroscopic
K1250A
closing rates in the absence of blocker (gray) and in the presence of 100 &#b5;M NPPB (brown), 80 mM MOPS&#e032; (green), or 100 &#b5;M NPPB + 80 mM MOPS&#e032; (striped).
Login to comment
121
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:121:36
status:
NEW
view ABCC7 p.Lys1250Ala details
In the presence of 100 &#b5;M NPPB,
K1250A
closing rate was accelerated by approximately twofold (Fig. 2, E [top and bottom traces, brown fit line and time constant] and F [brown bar]).
Login to comment
122
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:122:48
status:
NEW
view ABCC7 p.Lys1250Ala details
In contrast, 80 mM MOPS&#e032; neither affected
K1250A
closing rate (Fig. 2, E [top trace, green fit line and time constant] and F [green bar]), nor prevented the accelerating effect of 100 &#b5;M NPPB (Fig. 2, E [bottom trace, second application of NPPB] and F [striped bar]).
Login to comment
125
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:125:177
status:
NEW
view ABCC7 p.Lys1250Ala details
To dissect potential effects of 3NB (the NPPB head) and 3PP (the NPPB tail) on permeation and gating, we first characterized effects on permeation using locked-open macroscopic
K1250A
CFTR currents at two different voltages (&#e032;80 and 60 mV).
Login to comment
126
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:126:121
status:
NEW
view ABCC7 p.Lys1250Ala details
As expected, 3NB, which contains the pore-blocking carboxylate, dose-dependently suppressed currents through locked-open
K1250A
channels, and pore block was more pronounced at negative voltages, attesting to its voltage dependence (Fig. 3, A and B).
Login to comment
130
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:130:68
status:
NEW
view ABCC7 p.Lys1250Ala details
(A, B, F, G, I, and J) Decaying macroscopic currents of locked-open
K1250A
CFTR channels after removal of ATP, recorded at membrane potentials of &#e032;80 (A, F, and I) or 60 mV (B, G, and J) and responses to brief applications of various concentrations of 3NB (A and B, blue bars), 3PP-sulfate (F and G, red bars), or sulfate (I and J, green bars).
Login to comment
135
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:135:50
status:
NEW
view ABCC7 p.Lys1250Ala details
(D) Responses of decaying macroscopic locked-open
K1250A
CFTR current to brief applications of 32 mM 3NB (blue bars) at various membrane potentials.
Login to comment
142
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:142:36
status:
NEW
view ABCC7 p.Lys1250Ala details
Thus, using macroscopic locked-open
K1250A
CFTR currents elicited at either &#e032;80 (Fig. 4, A, C, and E) or 60 mV (Fig. 4, B, D, F), we compared fractional effects of coapplying 32 mM 3NB with 210 &#b5;M NPPB (Fig. 4, A and B, blue and brown bars), 20 mM 3PP with 210 &#b5;M NPPB (Fig. 4, C and D, red and brown bars), or 32 mM 3NB with 20 mM 3PP (Fig. 4, E and F, blue and red bars) with the fractional effects of the same three compounds when applied in isolation at the respective concentrations.
Login to comment
151
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:151:136
status:
NEW
view ABCC7 p.Lys1250Ala details
Indeed, at positive voltages only a small (&#e07a;10%) enhancement (rather than impairment) of the rate of ion flow through locked-open
K1250A
channels was observed at high 3PP concentrations (Fig. 3 G); a tentative fit to its dose-response curve yielded a K1/2 of &#e07a;10 mM (Fig. 3 H, red-yellow symbols and red fit line).
Login to comment
154
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:154:49
status:
NEW
view ABCC7 p.Lys1250Ala details
Indeed, at &#e032;80 mV, exposure of locked-open
K1250A
CFTR channels to sulfate caused substantial pore block (Fig. 3 I) with similarly anomalous dose dependence, yielding maximal block at &#e07a;5 mM sulfate (Fig. 3 H, green-cyan symbols and green abscissa).
Login to comment
167
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:167:52
status:
NEW
view ABCC7 p.Lys1250Ala details
(A-F) Responses of decaying macroscopic locked-open
K1250A
CFTR currents, recorded at membrane potentials of &#e032;80 (A, C, and E) or 60 mV (B, D, and F), to brief exposures to the following drug combinations: (A and B) 32 mM 3NB (blue bars) and/ or 210 &#b5;M NPPB (brown bars), (C and D) 20 mM 3PP (red bars) and/or 210 &#b5;M NPPB (brown bars), and (E and F) 32 mM 3NB (blue bars) and/or 20 mM 3PP (red bars).
Login to comment
219
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:219:224
status:
NEW
view ABCC7 p.Lys1250Ala details
The effects on average unitary conductance of WT CFTR, as observed in heavily (at 50 Hz) filtered current traces (Fig. 7 A), were consistent with the predictions of the macroscopic pore-block assays performed on locked open
K1250A
channels (Fig. 3, C and H).
Login to comment
228
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:228:126
status:
NEW
view ABCC7 p.Lys1250Ala details
To test this, we compared fractional effects of 3NB on steady-state macroscopic (I/Icontrol) and average unitary (i/icontrol)
K1250A
currents by applying 32 mM 3NB for extended time periods to channels gating at steady-state (in 10 mM ATP; Fig. 8 D, first and second 3NB applications) or briefly to locked-open channels after ATP removal (Fig. 8 D, third 3NB application, expanded in inset; this maneuver measures i/icontrol; compare with Fig. 3).
Login to comment
229
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:229:84
status:
NEW
view ABCC7 p.Lys1250Ala details
(Note that to increase the success rate of very long recordings, all experiments on
K1250A
gating shown in Fig. 8 were performed at &#e032;20 mV.)
Login to comment
230
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:230:39
status:
NEW
view ABCC7 p.Lys1250Ala details
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:230:336
status:
NEW
view ABCC7 p.Lys1250Ala details
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:230:362
status:
NEW
view ABCC7 p.Lys1250Ala details
Both application and removal of 3NB to
K1250A
channels, which are gating at steady-state, evoked simple monophasic current responses (Fig. 8 D; in contrast with Fig. 5 A), and the fractional current reduction under such conditions (Fig. 8 F, left gray bar) was well matched by the fractional effect on ATP removal in patches containing
K1250A
CFTR channels; the
K1250A
mutation (Fig. 8 C, cartoon, red stars) disrupts ATP hydrolysis (Fig. 8 C, cartoon, red cross; compare with Ramjeesingh et al. [1999]).
Login to comment
231
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:231:46
status:
NEW
view ABCC7 p.Lys1250Ala details
Indeed, the presence of 32 mM 3NB accelerated
K1250A
closing rate by two- to threefold (Fig. 8, A [blue vs. gray fit lines and time constants] and C [blue vs. gray bar]), to a similar extent as reported for NPPB (Fig. 8 C, brown bar; replotted from Csan&#e1;dy and T&#f6;r&#f6;csik [2014]).
Login to comment
232
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:232:107
status:
NEW
view ABCC7 p.Lys1250Ala details
In contrast, 20 mM 3PP, which did not significantly stimulate WT CFTR opening rate (Fig. 7 E), accelerated
K1250A
closing rate only slightly, by &#e07a;20% (Fig. 8, B and C [red vs. gray bar]).
Login to comment
233
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:233:192
status:
NEW
view ABCC7 p.Lys1250Ala details
If 3NB indeed acted as a catalyst for the C1O1 step, then the equilibrium between those two states (Fig. 8 G, cartoon, purple double arrow), as reflected by the open probability of the
K1250A
mutant (Keq = Po/(1 &#e032; Po)), Figure 8.ߓ Effects of 3NB and 3PP on gating rates under nonhydrolytic conditions.
Login to comment
234
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:234:22
status:
NEW
view ABCC7 p.Lys1250Ala details
(A and B) Macroscopic
K1250A
CFTR currents at &#e032;20 mV, elicited by exposures to 10 mM ATP (gray bars) in the absence of drug or in the presence of either 32 mM 3NB (A, blue bar) or 20 mM 3PP (B, red bar).
Login to comment
237
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:237:4
status:
NEW
view ABCC7 p.Lys1250Ala details
The
K1250A
mutation (cartoon, red stars) disrupts ATP hydrolysis in site 2 (red cross).
Login to comment
238
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:238:22
status:
NEW
view ABCC7 p.Lys1250Ala details
(D and E) Macroscopic
K1250A
CFTR currents elicited by 10 mM ATP at &#e032;20 mV and prolonged exposures to 32 mM 3NB (D, blue bars) or 20 mM 3PP (E, red bars) of channels gating at steady-state.
Login to comment
241
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:241:15
status:
NEW
view ABCC7 p.Lys1250Ala details
(F) Fractional
K1250A
CFTR currents at &#e032;20 mV in 32 mM 3NB (left pair of bars) or 20 mM 3PP (right pair of bars) applied during steady-state gating (gray bars) or in the locked-open state (yellow bars).
Login to comment
243
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:243:29
status:
NEW
view ABCC7 p.Lys1250Ala details
Fractional effects on Po for
K1250A
CFTR were calculated as in Fig. 5 (D and H).
Login to comment
252
ABCC7 p.Lys1250Ala
X
ABCC7 p.Lys1250Ala 25267914:252:68
status:
NEW
view ABCC7 p.Lys1250Ala details
Similarly, the small fractional effect of 20 mM 3PP on steady-state
K1250A
currents (Fig. 8, E and F [right gray bar]) was well explained by a similar small fractional increase in unitary conductance at this voltage (Fig. 8 F, right yellow bar), revealing no change in Po (Fig. 8 G, red bar).
Login to comment
343
ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 25267914:343:60
status:
NEW
view ABCC7 p.Gly551Asp details
A CFTR potentiator in patients with cystic fibrosis and the
G551D
mutation.
Login to comment